Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...

Brokerages remain positive on select stocks, with Citigroup maintaining a buy rating on Torrent Pharmaceuticals and Morgan Stanley keeping ...

Torrent Pharmaceuticals shares are expected to see activity. The Competition Commission of India has approved Torrent Pharma's plan to acqu...

JB Chemicals & Pharmaceuticals shares declined after KKR announced the sale of its stake to Torrent Pharma, valuing JB Pharma at Rs 25,689 ...

The drug maker had reported a net profit of Rs 142 crore in the year-ago period.Revenue for the quarter rose 12% YoY to Rs 1004 crore

JB Pharma, led by CEO Nikhil Chopra, forecasts 12-14% revenue growth and aims to increase Ebitda margins by 27-28% in FY25. The growth is d...

The Mumbai-based company reported operating earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 210 crore, up fro...

Citigroup maintained a buy rating on Nestle India post Q3 results with a target price of Rs 2900. The company reported steady revenue growt...

The drug maker had reported a net profit of Rs 106 crore in the year-ago period. Revenue for the quarter rose 7% YoY to Rs 845 crore The Mu...

Revenue for the quarter rose 9% YoY to Rs 882 crore. The Mumbai-based company reported operating earnings before interest, taxes, depreciat...

Domestic business revenue grew 17% YoY to Rs 489 crores in Q1FY24, despite sales for the acute business being impacted due to the delayed m...

Operating cash flow improved in FY23 to Rs 626 crores as compared to Rs 170 crores in FY22, strongly aided by the higher proportion of Indi...

The earnings before interest, tax, depreciation and ammortisation (EBITDA) rose 28% YoY to Rs 193 crore. The EBTIDA margin dropped 120 basi...

Revenues rose 36% YoY to Rs 809 crore in Q2FY23, compared to Rs 593 crore in Q2FY22.Earnings before interest, depreciation and taxes (EBITD...

The company reported net profit of Rs 119 crore during corresponding period of the previous year.The company attributed the drop in net pro...

KKR, which assumed control beginning this month, has made swift changes to the company's board of directors and senior management.

Lupin and Glenmark as clear winners with a likely upside from Para IV/niche opportunities, strong domestic franchise, low vulnerability to ...